# Andrew Lee

> Andrew Lee is a Series C investor at Northpond Ventures backing Biotechnology and Life Science. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Northpond Ventures](https://shizune.co/investors/profile/northpond-ventures)
- Location: San Francisco, United States
- Total investments: 6
- Last investment: Sep 2022
- Lead investor: 67%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/andrewhleephd/
- X (Twitter): https://twitter.com/ndrewhlee
- Website: https://northpondventures.com/

Andrew Lee is a Series C investor at Northpond Ventures in San Francisco focused on Biotechnology and Life Science. Andrew Lee is based out of Bethesda, Maryland and is the Managing Director of Northpond Ventures. Andrew previously worked at Booz Allen Hamilton as a Associate. Andrew Lee attended the Columbia University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Life Science | 2 | 33% |
| Farming | 1 | 17% |
| Genetics | 1 | 17% |
| Robotics | 1 | 17% |

11 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 2 | 33% |
| Seed | 1 | 17% |
| Series A | 1 | 17% |
| Series B | 1 | 17% |
| Funding Round | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| EnPlusOne Biosciences | EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics. | $12M | Seed | Sep 30, 2022 |  |
| 64x Bio | A comprehensive platform and product suite for advanced therapeutics. | $55M | Series A | Jan 19, 2022 |  |
| Culture Biosciences | Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California. | $80M | Series B | Oct 14, 2021 |  |
| Sound Agriculture | Sound Agriculture uses molecular discovery to create climate-resilient crops, enhancing harvest yields for growers. They also use an innovative life science approach to sustainably increase farming productivity. The company was founded in 2013 and headquartered in Emeryville, California. | $45M | Series C | Aug 19, 2021 |  |
| EnPlusOne Biosciences | EnPlusOne Biosciences provides innovative solutions for emerging RNA therapeutics. | $10M |  |  |  |
| Culture Biosciences | Culture Biosciences provides a platform of cloud-connected bioreactors, software tools, and process development services that support upstream bioprocess development for biotech and biopharma applications. The company’s offerings include remote experiment design, monitoring, and data analysis through an integrated cloud software interface pairedwith single-use bioreactors for microbial fermentation and cell culture experimentation. Its services encompass clone and strain screening, process optimization, characterization, and bioprocess modeling to help scientific teams refine and scale their workflows. Clients access real-time data and analytics to inform decisions and collaborate across teams using the platform’s tools. Culture Biosciences’s technology is used to advance development of therapeutics, synthetic biology products, and related bioprocesses. Culture Biosciences was founded in 2016 and is headquartered in San Francisco, California. |  | Series C |  |  |

6 of 6 investments shown.

## Co-investors
- [BoxGroup](https://shizune.co/investors/profile/boxgroup) — VC Fund, 2 deals together
- [Breakout Ventures](https://shizune.co/investors/profile/breakoutventures) — VC Fund, 2 deals together
- [Cultivian Sandbox Ventures](https://shizune.co/investors/profile/cultivian-sandbox-ventures) — VC Fund, 2 deals together
- [S32](https://shizune.co/investors/profile/section-32) — VC Fund, 2 deals together
- [Synthesis Capital](https://shizune.co/investors/profile/synthesis-capital-6f8f) — VC Fund, 2 deals together
- [Alix Ventures](https://shizune.co/investors/profile/alix-ventures) — VC Fund, 1 deal together

## About Northpond Ventures

VC Fund · Bethesda, United States

Northpond Ventures is a science-driven venture capital firm headquartered in Bethesda, Maryland. Our mission is to build a better tomorrow. Our investments are focused on life sciences, technology, and affiliated industries.

5 contacts available at Northpond Ventures.

| Name | Title | Profile |
| --- | --- | --- |
| Adam Wieschhaus | Director | https://shizune.co/investors/profile/adam-wieschhaus |
| Andrew Lee | Managing Director | https://shizune.co/investors/profile/andrew-lee-0d23 |
| Connor McDermott | Vice President | https://shizune.co/investors/profile/connor-mcdermott |
| Karthik Bolisetty | Senior Associate | https://shizune.co/investors/profile/karthik-bolisetty |
| Michael Rubin | Founder & CEO | https://shizune.co/investors/profile/michael-rubin-5 |

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does Andrew Lee invest in?

Andrew Lee invests primarily in Biotechnology, Life Science and Farming startups, most often at Series C and Seed stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Andrew Lee last invest?

The most recent investment recorded for Andrew Lee closed in Sep 2022. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co